Understanding Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC)

Lori Wirth, MD, provides an overview of differentiated thyroid cancer (DTC) and radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC).

Lori Wirth, MD, explains what regimen is considered to be the standard-of-care treatment for patients with advanced RAI-R-DTC.

Dr Lori Wirth discusses the design and data of two key clinical trials that led to the approval of the current treatment options for patients with advanced RAI-R-DTC.

Dr Lori Wirth details the common molecular alterations seen in patients with advanced RAO-R-DTC and which testing platforms she recommends.

Lori Wirth, MD, explains why the importance of molecular alterations in her treatment decision-making for a patient with advanced RAI-R-DTC, and the other factors she considers for an appropriate treatment.

Dr Lori Wirth highlights remaining unmet needs and challenges in the treatment of advanced RAI-R-DTC.